Phase 3 data showed comparable safety and efficacy of subcutaneous and intravenous induction regimens of guselkumab for moderately to severely active ulcerative colitis.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-oks-tremfya-ulcerative-colitis-2025a1000pd0?src=rss
Author :
Publish date : 2025-09-23 16:05:00
Copyright for syndicated content belongs to the linked Source.
